Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study

Cardiovascular Psychiatry and Neurology

Volumn , Issue , 2012, Pages

  Lancon, Christophe ^a,b   Dassa, Daniel ^c   Fernandez, Jessica ^a   Richieri, Raphaelle ^a,b   Padovani, Romain ^a,b   Boyer, Laurent ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c La Conception University Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CARDIOVASCULAR RISK; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LEARNING; LONG TERM MEMORY; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; METABOLIC SYNDROME X; PRIORITY JOURNAL; SCHIZOPHRENIA; SHORT TERM MEMORY;

EID: 84871396295     PISSN: 20900163     EISSN: 20900171     Source Type: Journal    
DOI: 10.1155/2012/204043     Document Type: Article

References (39)

1. Kopald B. E., Mirra K. M., Egan M. F., Weinberger D. R., Goldberg T. E., Magnitude of impact of executive functioning and IQ on episodic memory in Schizophrenia. Biological Psychiatry 2012 71 545 551
2. Nuechterlein K. H., Barch D. M., Gold J. M., Goldberg T. E., Green M. F., Heaton R. K., Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 2004 72 1 29 39 2-s2.0-7544234237 10.1016/j.schres.2004. 09.007 (Pubitemid 39452903)
3. Nasrallah H. A., Linkage of cognitive impairments with metabolic disorders in schizophrenia. American Journal of Psychiatry 2010 167 10 1155 1157 2-s2.0-77957956604 10.1176/appi.ajp.2010.10060838
4. Yaffe K., Kanaya A., Lindquist K., Simonsick E. M., Harris T., Shorr R. I., Tylavsky F. A., Newman A. B., The metabolic syndrome, inflammation, and risk of cognitive decline. The Journal of the American Medical Association 2004 292 18 2237 2242 2-s2.0-7744239901 10.1001/jama.292.18.2237 (Pubitemid 39473161)
5. Dik M. G., Jonker C., Comijs H. C., Deeg D. J. H., Kok A., Yaffe K., Penninx B. W., Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007 30 10 2655 2660 2-s2.0-35148828977 10.2337/dc06-1190 (Pubitemid 47547816)
6. Liu C. Y., Zhou H. D., Xu Z. Q., Zhang W. W., Li X. Y., Zhao J., Metabolic syndrome and cognitive impairment amongst elderly people in Chinese population: a cross-sectional study. European Journal of Neurology 2009 16 9 1022 1027 2-s2.0-68849106531 10.1111/j.1468-1331.2009.02640.x
7. van den Berg E., Kloppenborg R. P., Kessels R. P. C., Kappelle L. J., Biessels G. J., Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochimica et Biophysica Acta 2009 1792 5 470 481 2-s2.0-64249141005 10.1016/j.bbadis.2008.09. 004
8. Mitchell A. J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M., Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophrenia Bulletin. In press
9. Pramyothin P., Khaodhiar L., Metabolic syndrome with the atypical antipsychotics. Current Opinion in Endocrinology, Diabetes and Obesity 2010 17 5 460 466 2-s2.0-77956252303 10.1097/MED.0b013e32833de61c
10. Grant B. F., Hasin D. S., Chou S. P., Stinson F. S., Dawson D. A., Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 2004 61 11 1107 1115 2-s2.0-7744235961 10.1001/archpsyc.61.11.1107 (Pubitemid 39463411)
11. Koskinen J., Löhönen J., Koponen H., Isohanni M., Miettunen J., Prevalence of alcohol use disorders in schizophrenia-a systematic review and meta-analysis. Acta Psychiatrica Scandinavica 2009 120 2 85 96 2-s2.0-67649979716 10.1111/j.1600-0447.2009.01385.x
12. Meyer J. M., Nasrallah H. A., McEvoy J. P., Goff D. C., Davis S. M., Chakos M., Patel J. K., Keefe R. S. E., Stroup T. S., Lieberman J. A., The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 2005 80 1 9 18 2-s2.0-27744456032 10.1016/j.schres.2005.07.015 (Pubitemid 41587459)
13. Friedman J. I., Wallenstein S., Moshier E., Parrella M., White L., Bowler S., Gottlieb S., Harvey P. D., McGinn T. G., Flanagan L., Davis K. L., The effects of hypertension and body mass index on cognition in schizophrenia. American Journal of Psychiatry 2010 167 10 1232 1239 2-s2.0-77957934346 10.1176/appi.ajp.2010.09091328
14. APA: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 2000 4th Washington, DC, USA American Psychiatric Association
15. Kay S. R., Opler L. A., Fiszbein A., Significance of positive and negative syndromes in chronic schizophrenia. British Journal of Psychiatry 1986 149 439 448 2-s2.0-0022453385 (Pubitemid 16029659)
16. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O., The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991 86 9 1119 1127 2-s2.0-0025923219
17. Delis D. C., Kramer J. H., Kaplan E., Ober B. A., California Verbal Learning Test: Research Edition-Adult Version 1987 New York, NY, USA The Psychological Corporation
18. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005 112 17 2735 2752 2-s2.0-27444443876 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
19. Cheng A., Braunstein J. B., Dennison C., Nass C., Blumenthal R. S., Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clinical Cardiology 2002 25 5 205 212 2-s2.0-0036238632 (Pubitemid 34457362)
20. Bray G. A., Obesity is a chronic, relapsing neurochemical disease. International Journal of Obesity 2004 28 1 34 38 2-s2.0-0942268782 10.1038/sj.ijo.0802479 (Pubitemid 38141988)
21. Holden K. F., Lindquist K., Tylavsky F. A., Rosano C., Harris T. B., Yaffe K., Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiology of Aging 2009 30 9 1483 1489 2-s2.0-67650621405 10.1016/j.neurobiolaging.2007.11.024
22. Li X. L., Aou S., Oomura Y., Hori N., Fukunaga K., Hori T., Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002 113 3 607 615 2-s2.0-0037008873 10.1016/S0306-4522(02)00162-8 (Pubitemid 34874684)
23. Oomura Y., Hori N., Shiraishi T., Fukunaga K., Takeda H., Tsuji M., Matsumiya T., Ishibashi M., Aou S., Li X. L., Kohno D., Uramura K., Sougawa H., Yada T., Wayner M. J., Sasaki K., Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006 27 11 2738 2749 2-s2.0-33750091967 10.1016/j.peptides.2006.07.001 (Pubitemid 44584418)
24. Reitz C., Tang M. X., Manly J., Mayeux R., Luchsinger J. A., Hypertension and the risk of mild cognitive impairment. Archives of Neurology 2007 64 12 1734 1740 2-s2.0-37149016808 10.1001/archneur.64.12.1734 (Pubitemid 350254935)
25. Manning V., Betteridge S., Wanigaratne S., Best D., Strang J., Gossop M., Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder. Schizophrenia Research 2009 114 1-3 98 104 2-s2.0-69849083727 10.1016/j.schres.2009.05.020
26. Bowie C. R., Serper M. R., Riggio S., Harvey P. D., Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophrenia Bulletin 2005 31 1 175 182 2-s2.0-20844433867 10.1093/jschbul/sbi001 (Pubitemid 41214366)
27. Olincy A., Harris J. G., Johnson L. L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G. O., Leonard S., Stevens K. E., Stevens J. O., Martin L., Adler L. E., Soti F., Kem W. R., Freedman R., Proof-of-concept trial of an 7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 2006 63 6 630 638 2-s2.0-33744911665 10.1001/archpsyc.63.6.630 (Pubitemid 43848294)
28. D'Souza M. S., Markou A., Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 2012 62 1564 1573 2-s2.0-79951567725 10.1016/j.neuropharm. 2011.01.044
29. Whitmer R. A., Sidney S., Selby J., Johnston S. C., Yaffe K., Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005 64 2 277 281 2-s2.0-12744273863
30. Smith M. J., Wang L., Cronenwett W., Goldman M. B., Mamah D., Barch D. M., Csernansky J. G., Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. Schizophrenia Research 2011 131 174 183 2-s2.0-79957916330 10.1016/j.schres.2011.05.014
31. Drake R. E., Essock S. M., Shaner A., Carey K. B., Minkoff K., Kola L., Lynde D., Osher F. C., Clark R. E., Rickards L., Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services 2001 52 4 469 476 2-s2.0-0035069292 10.1176/appi.ps.52.4.469 (Pubitemid 32275306)
32. Essock S. M., Drake R. E., Burns B. J., A research network to evaluate assertive community treatment: introduction. The American Journal of Orthopsychiatry 1998 68 2 176 178 2-s2.0-0032044515
33. Picciotto M. R., Zoli M., Nicotinic receptors in aging and dementia. Journal of Neurobiology 2002 53 4 641 655 2-s2.0-0036890784 10.1002/neu.10102 (Pubitemid 35375593)
34. Jurado-Barba R., Morales-Muñoz I., del Manzano B. A., Fernández-Guinea S., Caballero M., Martínez-Gras I., Rubio-Valladolid G., Relationship between measures of inhibitory processes in patients with schizophrenia: role of substance abuse disorders. Psychiatry Research 2011 190 187 192 2-s2.0-79959362155 10.1016/j.psychres.2011.06.002
35. Ochoa E. L. M., Lasalde-Dominicci J., Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cellular and Molecular Neurobiology 2007 27 5 609 639 2-s2.0-34447134086 10.1007/s10571-007-9149-x (Pubitemid 47038107)
36. Adachi H., Yanai H., Hirowatari Y., The underlying mechanisms for olanzapine-induced hypertriglyceridemia. Journal of Clinical Medicine Research 2012 4 206 208
37. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Bernardo M., Kirkpatrick B., Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Research 2012 198 2 212 215
38. Nasrallah H. A., Newcomer J. W., Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Journal of Clinical Psychopharmacology 2004 24 5, supplement 1 S7 S14 2-s2.0-4644354707 10.1097/01.jcp.0000142282.62336.e9 (Pubitemid 39265949)
39. Meltzer H. Y., McGurk S. R., The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999 25 2 233 255 2-s2.0-0032977410 (Pubitemid 29272503)